You can read the full article at LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism
Its hard to estimate exactly how much Americans needle aversion has tamped down their uptake of GLP-1 drugs
Dose adjustments, slower titration [dose increase] schedules, hydration strategies, nutrition counseling, and other symptom-management approaches can often help improve tolerability
Disclaimer None
Power calculations suggest that previous studies would have had limited power to detect an effect size similar to that identified in our study (Supplementary Table 23), and also differed in terms of drug type, disease cohort and analytical choices
However, many insurance providers require that patients continue treatment as prescribed for weight maintenance in order to stay eligible for coverage